Your browser doesn't support javascript.
Antimicrobial resistance: A challenge awaiting the post-COVID-19 era.
Lobie, Tekle Airgecho; Roba, Aklilu Abrham; Booth, James Alexander; Kristiansen, Knut Ivan; Aseffa, Abraham; Skarstad, Kirsten; Bjørås, Magnar.
  • Lobie TA; Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway. Electronic address: teklemicro@gmail.com.
  • Roba AA; College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
  • Booth JA; Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Kristiansen KI; Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Aseffa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Skarstad K; Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Bjørås M; Department of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Int J Infect Dis ; 111: 322-325, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-2113675
ABSTRACT
Microbe exposure to pharmaceutical and non-pharmaceutical agents plays a role in the development of antibiotic resistance. The risks and consequences associated with extensive disinfectant use during the COVID-19 pandemic remain unclear. Some disinfectants, like sanitizers, contain genotoxic chemicals that damage microbial DNA, like phenol and hydrogen peroxide. This damage activates error-prone DNA repair enzymes, which can lead to mutations that induce antimicrobial resistance. Public health priority programs that have faced drug-resistance challenges associated with diseases, such as tuberculosis, HIV, and malaria, have given less attention to risks attributable to the COVID-19 pandemic. Pathogen-specific programs, like the directly observed treatment strategy designed to fight resistance against anti-tuberculosis drugs, have become impractical because COVID-19 restrictions have limited in-person visits to health institutions. Here, we summarized the key findings of studies on the current state of antimicrobial resistance development from the perspective of current disinfectant use. Additionally, we provide a brief overview of the consequences of restricted access to health services due to COVID-19 precautions and their implications on drug resistance development.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Resistance, Bacterial / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Resistance, Bacterial / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article